Novel Cooled Focal Therapy Achieves Short-Term Localized Prostate Cancer Control - Oncology Nurse Advisor The phase 2 ProFocal Laser Therapy for Prostate Tissue Ablation (PFLT-PC) trial tested a cooled laser focal therapy device for intermediate-risk prostate cancer treatment.

Phase 2: Cooled focal therapy shows 88% success in #prostatecancer at 12 mo. 🔬

• No urinary incontinence 📊
• 100% potency retention
• High QoL profile

Via @bjuijournal.bsky.social @renalurologynews.bsky.social.

Read more: https://bit.ly/4cB2rF9

#GUsm #MedEd #Oncology #pcsm

Lots of exciting data at #ESMO25. Here are the 3 Presidential Symposia presentations. Tomorrow: DESTINY-Breast11 (high-risk HER2+ eBC), DESTINY-Breast05 (high-risk HER2+), KEYNOTE-05 (MIBC), KEYNOTE-B96 (ovarian). #BCSM #Bladdercancer #gusm #ovariancancer #gynsm

CONTACT-03: subgroup analysis of 2L cabozantinib ± atezolizumab in aRCC - VJOncology Cristina Suárez, MD, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain, discusses a subgroup analysis from the CONTACT-03 study (NCT04338269)...

🎥 Cristina Suárez (@vhio.bsky.social) discusses CONTACT-03 subgroup analysis on cabozantinib ± atezolizumab in advanced #RCC post-immunotherapy at #ASCO25. Key insights for treatment sequencing strategies.

🔗 buff.ly/uix2tBW

@ascocancer.bsky.social #KidneyCancer #RCC #GUsm #UroOnc #UroSoMe

🚨In <1 wk, it’s #GU25🚨 Let’s discuss the current SoC ➕ how the data will change/reinforce our practice at #AdvInOnc25:

- Bladder Ca
- Prostate Ca
- RCC

*Join us LIVE*
📅 Date: Feb 12, 2025
⏰ Time: 6:00-8:00PM
📝 bit.ly/guaio25

#OncSky #MedSky #gusm #Oncology #Cancer #CanSky

Approval is just a start, managing AEs for these💊matters as much. #ToxCheck for commonly used ADCs w/ Drs. @erikahamilton9.bsky.social ➕ TianZhang!

Full 🗣️
- “Oncology Brothers”Podcast
- oncbrothers.com/toxcheck-adc...
- www.oncologynewscentral.com/video/tox-ch...

#bcsm #gusm #OncSky #MedSky